News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2025 - 09 - 25

Huiguan Biotechnology Completes Pre-A+ Financing Round | Feng Investment News

Recently, Wuhan Huiguan Biotechnology Co., Ltd. (hereinafter referred to as "Huiguan Biotechnology") completed its Pre-A+ financing round. This round was co-led by Optics Valley Industrial Investment and Yangtze River Capital Venture Capital, with joint participation from Optics Valley Financial Holdings. The funds will primarily be used for product R&D, market expansion, and team growth, further consolidating the company's leading position in the high-end biomedical imaging field.Founded in September 2022, Huiguan Biotechnology was incubated from the team of Professor Fei Pe...

浏览次数：1

查看详情>>

发布时间: 2025 - 09 - 23

Powerful Alliance! Haplox and PanGene Medicine Reach Strategic Cooperation, Opening a New Chapter in

On September 22, Shenzhen PanGene Medicine Co., Ltd. (hereinafter referred to as "PanGene Medicine"), a domestic professional immunomics testing service company, officially reached a strategic cooperation agreement with Shenzhen Haplox Biotechnology Co., Ltd. (hereinafter referred to as "Haplox"), a leading national high-tech enterprise in precision medicine and genetic big data, recognized as a "Specialized, Refined, Distinctive, and Innovative" (SRDI) "Little Giant" company.The collaboration focuses on immunome NGS sequencing technology, specifically t...

浏览次数：0

查看详情>>

发布时间: 2025 - 09 - 22

Global First! Frontier Biotech's Dual-Target siRNA Drug FB7011 Brings New Treatment Option for IgA N

From September 17 to 20, 2025, the 18th International IgA Nephropathy Symposium (IIgANN 2025) was held in Prague, Czech Republic. At the conference, Frontier Biotech presented, for the first time as an oral report, the preclinical data for FB7011, a self-developed dual-target small nucleic acid drug with global first-in-class (FIC) potential. This drug simultaneously targets MASP-2, a key protein in the complement system's lectin pathway, and CFB, a key protein in the alternative pathway, blocking the pathogenesis of IgA nephropathy by precisely intervening in the abnormal activation of th...

浏览次数：1

查看详情>>

发布时间: 2025 - 09 - 19

IASO Biotherapeutics Releases Groundbreaking 3-Year Follow-Up Data for CAR-T Product Fucaso® in Mult

According to the study data based on enrollment, as of December 31, 2024, a total of 109 patients received treatment with Fucaso®. The median number of prior lines of therapy was 4. Among these patients, 12.8% had EMD, and 11% had received prior BCMA CAR-T therapy. After receiving lymphodepleting preconditioning with cyclophosphamide and fludarabine for three consecutive days, patients received a single infusion of CAR-T cells (1×10⁶ cells/kg).Among the 107 evaluable patients, the overall response (ORR) rate was 96.3%, with a complete response (CR) or stringent complete response (sCR...

浏览次数：0

查看详情>>